Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital

被引:7
作者
Elberdin, L. [1 ]
Fernandez-Torres, Rm [2 ]
Paradela, S. [2 ]
Blanco, E. [2 ]
Outeda, M. [1 ]
Martin, I. [1 ]
Fonseca, E. [2 ]
机构
[1] UDC, Inst Invest Biomed A Coruna INIBIC, CHUAC, Dept Pharm, La Coruna, Spain
[2] UDC, Inst Invest Biomed A Coruna INIBIC, CHUAC, Dept Dermatol, La Coruna, Spain
关键词
Ustekinumab; psoriasis; biologic therapy; real-world setting; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; PRACTICAL EXPERIENCE; DOUBLE-BLIND; EFFICACY; ETANERCEPT; SAFETY; ADALIMUMAB; UK;
D O I
10.1080/09546634.2019.1605140
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Efficacy and safety profiles of ustekinumab have been proved in numerous clinical trials. However, relevant variations with daily practice have been shown and few studies value the long-term response maintenance. Objective: To evaluate the efficacy of long-term ustekinumab therapy in patients with moderate-to-severe plaque-type psoriasis in a real-world setting. Methods: Observational retrospective follow-up study including, patients receiving ustekinumab at least 3 months in our department. Efficacy was expressed as percentage of patients achieving Psoriasis area and severity index (PASI) 50, PASI75, and PASI90 and maintaining PASI <= 5, <= 3, and 0 every 3 months during the first year of treatment, and every 12 months to the end of follow-up or to withdrawal from the study. Results: Sixty-one patients. Fifty patients had previously been treated with other biologic therapies. The percentage of patients maintaining PASI90 was 72.1, 78.3, 70.0, 83.3, 96.2, 91.7, and 100.0%, and PASI value maintained 0 in 68.9, 73.9, 67.50, 80.6, 96.2, 91.7, and 100.0% at 3, 12, 24, 36, 60, 84, and 96 months. Ustekinumab was discontinued in 26.2% of patients. No patients were withdrawn because of adverse events. Conclusions: This real world-setting study shows maintenance of long-term efficacy and safety of ustekinumab treatment in moderate-severe plaque psoriasis in daily practice through 8 years.
引用
收藏
页码:698 / 701
页数:4
相关论文
共 11 条
[1]   Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting [J].
Fonseca, Eduardo ;
Iglesias, Raquel ;
Paradela, Sabela ;
Fernandez-Torres, Rosa M. ;
Elberdin, Laida .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (03) :217-222
[2]   Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study [J].
Kimball, A. B. ;
Papp, K. A. ;
Wasfi, Y. ;
Chan, D. ;
Bissonnette, R. ;
Sofen, H. ;
Yeilding, N. ;
Li, S. ;
Szapary, P. ;
Gordon, K. B. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (12) :1535-1545
[3]   Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the UK and Ireland [J].
Laws, P. M. ;
Downs, A. M. ;
Parslew, R. ;
Dever, B. ;
Smith, C. H. ;
Barker, J. N. ;
Moriarty, B. ;
Murphy, R. ;
Kirby, B. ;
Burden, A. D. ;
McBride, S. ;
Anstey, A. V. ;
O'Shea, S. ;
Ralph, N. ;
Buckley, C. ;
Griffiths, C. E. M. ;
Warren, R. B. .
BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (01) :189-195
[4]  
Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4
[5]   Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA [J].
Maria Fernandez-Torres, Rosa ;
Paradela, Sabela ;
Fonseca, Eduardo .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2014, 25 (01) :54-56
[6]   Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) [J].
Menter, A. ;
Papp, K. A. ;
Gooderham, M. ;
Pariser, D. M. ;
Augustin, M. ;
Kerdel, F. A. ;
Fakharzadeh, S. ;
Goyal, K. ;
Calabro, S. ;
Langholff, W. ;
Chavers, S. ;
Naessens, D. ;
Sermon, J. ;
Krueger, G. G. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 (07) :1148-1158
[7]   Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) [J].
Papp, Kim A. ;
Langley, Richard G. ;
Lebwohl, Mark ;
Krueger, Gerald G. ;
Szapary, Philippe ;
Yeilding, Newman ;
Guzzo, Cynthia ;
Hsu, Ming-Chun ;
Wang, Yuhua ;
Li, Shu ;
Dooley, Lisa T. ;
Reich, Kristian .
LANCET, 2008, 371 (9625) :1675-1684
[8]   Ustekinumab in clinical practice: response depends on dose and previous treatment [J].
Ruiz Salas, V. ;
Puig, L. ;
Alomar, A. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (04) :508-513
[9]   Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre [J].
Warren, R. B. ;
Brown, B. C. ;
Lavery, D. ;
Griffiths, C. E. M. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (04) :859-862
[10]   Biologic therapies for psoriasis: practical experience in a UK tertiary referral centre [J].
Warren, R. B. ;
Brown, B. C. ;
Lavery, D. ;
Ashcroft, D. M. ;
Griffiths, C. E. M. .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (01) :162-169